The current financial score of Sagimet Biosciences Inc is 8.15. Its financial status is robust, and its operating efficiency is high.
The current valuation score of Sagimet Biosciences Inc is 7.61. Its current P/E ratio is -6.80, which is -85.72% below the recent high of -0.97 and -131.09% above the recent low of -15.71.
The current earnings forecast score of Sagimet Biosciences Inc is 8.62. The average price target is 27.55, with a high of 56.00 and a low of 7.00.
The current price momentum score of Sagimet Biosciences Inc is 4.41. Currently, the stock price is trading between the resistance level at 10.81 and the support level at 8.05, making it suitable for range-bound swing trading.
The current institutional shareholding score of Sagimet Biosciences Inc is 3.00. The latest institutional shareholding proportion is 25.99%, representing a quarter-over-quarter decrease of 36.48%.
The current risk assessment score of Sagimet Biosciences Inc is 5.09. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.